

**NOCRI**

NIHR Office for  
Clinical Research  
Infrastructure

# **Funding for diagnostic test development and opportunities to collaborate with academia.**

Mr Ravi Chana  
NIHR Office for Clinical Research Infrastructure (NOCRI)

## **NOCRI**

NIHR Office for  
Clinical Research  
Infrastructure

## **Overview**

**RESEARCH FUNDING**

**NIHR INFRASTRUCTURE TO SUPPORT EVIDENCE  
GENERATION**

**NEW MODELS FOR EFFECTIVE PARTNERSHIP**



**NOCRI**

NIHR Office for  
Clinical Research  
Infrastructure

# FUNDING LINKED TO IVD AND MEDICAL DEVICE CLINICAL RESEARCH & DEVELOPMENT

## Funding Sources/Organisations

- Basic Research
  - Medical Research Council (MRC)
  - Engineering Physical Sciences Research Council (EPSRC)
  - Innovate UK (Formerly Technology Strategy Board TSB)
  - Horizon 2020 (FP7)
- Clinical Research
  - National Institute for Health Research (NIHR)
  - Innovate UK
  - NHS England (SBRI)
  - Charities
  - Horizon 2020
  - ...



## NIHR Research Programmes

- The NIHR funds a range of programmes addressing a broad range of health priorities
- Funding is based on the quality and relevance of the research to personal social services, public health and the NHS
- Calls are issued for:
  - commissioned research to address specific topic areas
  - researcher-led research to fund questions proposed directly by researchers
  - themed calls to meet an identified health challenge or government priority

# NIHR Funding Streams

## Commissioned Research

- Innovation for Innovation (i4i) – Challenge Awards
- Efficacy Mechanism Evaluation (EME)
- Health Technology Assessment (HTA)
- Health Service and Delivery Research (HS&DR)
- Public Health Research

## Research-Led Research

- Invention for Innovation (i4i)
- Efficacy Mechanism Evaluation (EME)
- Health Technology Assessment (HTA)
- Health Service and Delivery Research (HS&DR)
- Public Health Research
- Research for Patients Benefit (RfPB)
- Programme Grants for Applied Research
- Programme Development Grants

# NIHR Funding Streams

## NIHR Clinical Commissioning Facility (NIHR-CCF)

- Invention for Innovation (i4i)
- Programme Grants for Applied Research (PGfAR)
- Programme Development Grants (PDG)
- Research for Patient Benefit (RfPB)
- Health Innovation Challenge Fund (HICF) – Co-funded between DH & Wellcome Trust

## NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC)

- Efficacy and Mechanism Evaluation (EME) Programme
- Health Services and Delivery Research (HS&DR) Programme
- Health Technology Assessment (HTA) Programme
- Public Health Research (PHR) Programme
- Systematic Reviews (SR) Programme
- NIHR Clinical Trials Unit (CTU) Support Funding



## NOCRI

NIHR Office for  
Clinical Research  
Infrastructure

	Research programme								
Broad research area	EME	HS&DR	HTA	i4i	PGfAR	PDG	PHR	RfPB	SR
Public health	✓	✓	✓	✓	✓	✓	✓	✓	✓
Health services and organisation	✗	✓	✓	✗	✓	✓	✗	✓	✓
Clinical evaluation and translation	✓	✗	✓	✓	✓	✓	✗	✓	✓
Technology development	✗	✗	✗	✓	✗	✗	✗	✗	✗
Types of evidence									
Evidence synthesis	✗	✓	✓	✗	✓	✓	✓	✓	✓
Evidence generation	✓	✓	✓	✓	✓	✓	✓	✓	✗
'Programmes' of research	✗	✓	✗	✗	✓	✓	✓	✗	✓


## NOCRI

NIHR Office for  
Clinical Research  
Infrastructure

### Research programme

	EME	HS&DR	HTA	i4i	PGfAR	PDG	PHR	RfPB	SR
Calls and competitions (number of opportunities to apply per year)									
Researcher-led	3	3	3	2	2	2	3*	3	1*
Commissioned	3	3	3	2	N/A	N/A	3*	N/A	N/A
Themed	Frequency and participating programmes as advertised								
Funding amounts and periods									
Funding limit**	No limit	No limit	No limit	No limit	No limit***	£100k	No limit	£350k <sup>†</sup>	£400k
Period of funding	No fixed period	No fixed period	No fixed period	Up to 3 years	No fixed period***	0-18 months	No fixed period	Up to 3 years	Up to 3 years

# Role of NIHR research in the innovation pathway





## Overview

- In simple terms:
  - MRC: Basic science (can it work?)
  - i4i: Technical development (how does it work?)
  - EME: Evaluation (does it work?)
  - HTA: Cost-effectiveness (is it worth it?)

**NOCRI**

NIHR Office for  
Clinical Research  
Infrastructure

# NIHR Invention for Innovation (i4i)

## i4i Programme

- Support for R&D and clinical adoption of innovative healthcare technologies
- Funding for collaborative projects involving academics, clinicians or companies
- Two funding streams
  - i4 Product Development Awards
  - i4i Challenge Awards



## Project Eligibility

- Minimum of two organisations involved – HEI, NHS Trust, Industry
- Lead applicants and collaborators must be based in England or Wales
- Sub-contractors may be from abroad
- Up to three years in duration
- No upper funding limits
- No work packages including animal studies
- Project must have progressed beyond basic research

### Not supported:

- Drug development, incremental R&D, clinical trials of fully developed products or interventions, impact of service delivery, infrastructure, etc

## Assessment Criteria

- Clinical need, health economic case & NHS adoption
- Project plan
- Strength of the research/management teams
- IP
- Commercial strategy
- PPI
- Quality of outline and full applications

## Record and Upcoming Calls

- To date, i4i has funded over 70 projects in the fields of medical devices and *in vitro/in vivo* diagnostics with a spend of £44 million
- 9<sup>th</sup> call for Product Development Awards
- 4<sup>th</sup> call for Challenge Awards
- Opening November, closing January, dates to be confirmed



NOCRI

NIHR Office for  
Clinical Research  
Infrastructure

## Contact Details

Website: <http://www.ccf.nihr.ac.uk/i4i/>

Email: [i4i.programme@nihr-ccf.org.uk](mailto:i4i.programme@nihr-ccf.org.uk)

Tel: 020 8843 8015

NIHR Central Commissioning Facility  
Grange House  
15 Church Street  
Twickenham TW1 3NL

**NOCRI**

NIHR Office for  
Clinical Research  
Infrastructure

# NIHR EFFICACY MECHANISM EVALUATION (EME)

## Efficacy and Mechanism Evaluation

### Aim:

- Support excellent clinical science with an ultimate view to improving health or patient care

### Dual Approach:

- “Science driven” – examine the efficacy of a technology intervention (i.e. pharmaceutical, diagnostic test, surgical or psychological therapies, or public health measures) and/or explore its mechanisms of action
- Clear patient focussed outcomes in areas of need for health care research

## EME – Programme Remit

Support studies in patients which seek to:

- Evaluate the clinical efficacy of interventions (where proof of concept in humans has already been achieved)
- Add significantly to our understanding of biological or behavioural mechanisms and processes
- Explore new scientific or clinical principles

Within the main clinical intervention study, if relevant to the EME remit, will support:

- Development or testing of new methodologies
- Studies that use validated surrogate markers as indicators of health outcome
- Laboratory based, or similar embedded studies
- Pilot and feasibility studies

## EME – Programme Remit

The EME Programme will not support:

- Confirmatory studies or trials of incremental modifications to existing medical interventions
- Proof-of-concept, proof-of-mechanism in humans, nor 'confidence in effect' studies
- Research involving animals
- Commercial collaborations are welcome in applications, however, the lead applicant must be from academia or the NHS
- The funding projects range from £120,000 to £3.1 million and the durations range from 18 to 66 months

## EME – Open Commissioned Calls

Topic	Deadline	Commissioning brief	Guidance notes	Apply
14/142 Mechanisms of action of health interventions*	7 October 2014, by 1pm	<a href="#">Access commissioning brief (pdf, 131.04 KB)</a>	<a href="#">Access guidance notes (pdf, 360.59 KB)</a>	<a href="#">Apply</a>
14/144 Bowel control and faecal incontinence in adults	7 October 2014, by 1pm	<a href="#">Access commissioning brief (pdf, 133.11 KB)</a>	<a href="#">Access guidance notes (pdf, 304.14 KB)</a>	<a href="#">Apply</a>
14/145 Pituitary and/or adrenal disorders and related diseases	7 October 2014, by 1pm	<a href="#">Access commissioning brief (pdf, 132.66 KB)</a>	<a href="#">Access guidance notes (pdf, 304.14 KB)</a>	<a href="#">Apply</a>
14/146 Renal failure resulting from intrinsic renal diseases	7 October 2014, by 1pm	<a href="#">Access commissioning brief (pdf, 132.97 KB)</a>	<a href="#">Access guidance notes (pdf, 304.14 KB)</a>	<a href="#">Apply</a>
14/147 Wound healing	7 October 2014, by 1pm	<a href="#">Access commissioning brief (pdf, 132.28 KB)</a>	<a href="#">Access guidance notes (pdf, 304.14 KB)</a>	<a href="#">Apply</a>



## EME - Examples

**Developing a novel, biopsy-based diagnostic for patient stratification: A Randomised, open labelled study in anti-TNFalpha inadequate responders to investigate the mechanisms for Response, Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis patients**

*Professor Costantino Pitzalis (University of London) 33 months from 1<sup>st</sup> December 2012 (£1,002,635)*

**Aims to establish whether a sample of the joint lining can predict which patients will respond to treatment.**

***Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis (ENDCaP-C)***

*Dr Glenn Matthews (University of Birmingham) 24 months from 1<sup>st</sup> February 2013 (£1,552,675).*

**Aims to develop a diagnostic test to be used alongside colonoscopy, and so improve the detection of tumours at an early stage.**

## EME – Key Points and Resources

- Have good preliminary data to justify your proposal
  - Gather a team with relevant scientific and project management skills
  - Have an appropriate study design and strong statistical support
  - Be realistic and accurate when costing the study
  - Talk your proposed study through with EME before submitting an application
- 
- EME website: <http://www.eme.ac.uk/index.asp>
  - EME video/podcast:  
<http://www.youtube.com/watch?v=ICtXbGgc5nU>
  - EME secretariat: contact us at [info@eme.ac.uk](mailto:info@eme.ac.uk) or 02380 594304

**NOCRI**

NIHR Office for  
Clinical Research  
Infrastructure

# NIHR Health Technology Assessment (HTA)

## What is a “Health Technology”?

The term ‘health technology’ covers a range of methods used to promote Health, prevent and treat disease and improve rehabilitation and long term care including:

- Drugs: such as antidepressants, contraceptives, antibiotics
- Devices: such as pacemakers, dialysis machines, hearing aids
- Procedures: such as surgical techniques, physiotherapy, counselling
- Screening: for cancer, sexually transmitted diseases, stroke
- Evaluation of diagnostic tests

## Remit

- The HTA Programme supports research that is immediately useful to clinical practice and NHS decision makers
- HTA research is undertaken when there is evidence to show the technology has demonstrated efficacy but there is uncertainty around its clinical and cost effectiveness in a real life NHS setting in comparison to the current best alternative
- There may also be uncertainty around its place in the existing care pathway

## HTA Contact

- National Institute for Health Research -  
Evaluation, Trials and Studies Coordinating  
Centre

University of Southampton

Alpha House, Enterprise Road

Southampton SO16 7NS

Tel: 023 8059 5586


Email: [hta@hta.ac.uk](mailto:hta@hta.ac.uk)

Web: [www.nets.nihr.ac.uk/hta](http://www.nets.nihr.ac.uk/hta)




# Other Funding Streams

# Finance for Innovation – KTN




**EUROPE**  
[www.FP7uk.co.uk](http://www.FP7uk.co.uk)


**INNOVATE UK (formerly TSB)**  
**NATIONAL**  
[www.innovateuk.org](http://www.innovateuk.org)






**Devolved Administrations /Regional Funding**



**DoH/NIHR**  
[www.nihr-ccf.org.uk/site/programmes/i4i](http://www.nihr-ccf.org.uk/site/programmes/i4i)



**RESEARCH COUNCILS**  
[www.rcuk.ac.uk](http://www.rcuk.ac.uk)



NOCRI

NIHR Office for  
Clinical Research  
Infrastructure

# Innovate UK

Technology Strategy Board  
Driving Innovation



## Innovate UK - Biomedical Catalyst

- Joint Technology Strategy Board (TSB) and Medical Research Council (MRC) programme
  - £90m Innovate UK: New programme for business
  - £90m MRC: Rebranding of DPFS/DCS for academics
- Small and medium-sized commercial enterprises (SMEs), and researchers looking to work either individually or in collaboration to develop solutions to healthcare challenges.
- An integrated translational funding programme that can support innovative ideas
  - Any sector or discipline - that demonstrate the potential to provide significant positive healthcare and economic impact.

# Innovate UK – Biomedical Catalyst

## Feasibility award

This grant enables the exploration and evaluation of the commercial potential of an early-stage scientific idea, through:

- review of research evidence and identification of application
- assessment of business opportunity
- investigation of intellectual property position
- experimental studies to validate initial concepts or existing pre-clinical work
- scoping for further development.

### Key features

#### Business-led applications:

Duration – up to 12 months

Maximum grant – £150k

Funding proportion – up to 75% of total eligible project costs

#### Academic-led applications:

Confidence in Concept Awards will be made available to researchers in major universities

## Early-stage award

This grant is to evaluate the technical feasibility of an idea and establish proof of concept in a model system, through:

- experimental evaluation (lab-scale)
- initial demonstration using *in vitro* and *in vivo* models (not human trials)
- exploration of potential production mechanisms
- early-stage prototyping
- product development planning
- intellectual property protection\*.

### Key features

#### Business-led applications:

Duration – up to three years

Maximum grant - £2.4m

Funding proportion – SME's up to 60% of total eligible project costs

#### Academic-led applications:

Duration – up to three years

Maximum grant – £3m

Funding proportion – awarded at RCUK fEC rules

## Late-stage award

This grant takes a well-developed concept and demonstrates its effectiveness in a relevant environment through:

- initial human proof-of-concept studies
- demonstration of clinical utility and effectiveness
- demonstration of safety and efficacy (including phase I and II clinical trials)
- development of production mechanisms
- prototyping
- market testing
- intellectual property protection\*.

### Key features

#### Business-led applications:

Duration – up to three years

Maximum grant - £2.4m

Funding proportion – SME's up to 60% of total eligible project costs

#### Academic-led applications:

Duration – no formal limit

Maximum grant – no formal limit

Funding proportion – awarded at RCUK fEC rules


## Smart

- Co-funding for UK-based pre-start-ups, start-ups, micro businesses and SMEs - science, engineering and technology R&D projects leading to successful new products, processes and services
- The Smart programme is 'always open' and is not restricted to projects in certain themes or sectors.
- Three types of grant are available:
  - **Proof of market**
  - **Proof of concept**
  - **Development of prototype**



**NOCRI**

NIHR Office for  
Clinical Research  
Infrastructure



## Common Issues with Applications

- Sample size/power calculation
- Recruitment
- Lack of preliminary data
- Study design
  - Choice of patients/population: inclusion/exclusion
  - Endpoints
  - Randomisation
  - Standardisation of intervention across centres
  - Dosage
- Study team
- Justification of costs
- Lack of embedded PPI involvement
- Unclear relationship with industry
- Sticking to the call brief

## What should you do?

- Sign up for NIHR Funding Bulletins
  - <http://www.nets.nihr.ac.uk/news/?a=2936>
- Download the NIHR Funding Booklet
  - <http://www.nihr.ac.uk/documents/about-NIHR/NIHR-Publications/NIHR-funding-opportunities-booklet.pdf>
- View Open NIHR Funding Calls
  - <http://www.nihr.ac.uk/funding-opportunities/>

**NOCRI**

NIHR Office for  
Clinical Research  
Infrastructure

# NIHR INFRASTRUCTURE TO SUPPORT EVIDENCE GENERATION

NOCRI

NIHR Office for  
Clinical Research  
Infrastructure

# NIHR Research Infrastructure

Invention

Evaluation

Adoption

Early-phase clinical research

Late-phase clinical  
research

NIHR Biomedical Research Centres

NIHR Biomedical Research Units

NIHR Clinical Research Facilities

Experimental Cancer Medicine Centres

Healthcare Technology Cooperatives

Diagnostic Evidence Cooperatives

NIHR Clinical Research Network

NIHR Collaborations for Leadership in  
Applied Health Research & Care

> £0.5 billion p.a. investment in  
relevant infrastructure to  
support clinical research at all  
points in development pipeline

NOCRI

NIHR Office for  
Clinical Research  
Infrastructure

## Biomedical Research Centres (BRCs)

£800million Government investment to support NIHR Centres and Units - the largest ever commitment to early stage health research

Oxford

Marsden\*

Maudsley\*

Southampton

Newcastle upon Tyne

Cambridge

Imperial

University College

Great Ormond St\*

Moorfields\*

Guy's and St Thomas'






NOCRI

NIHR Office for  
Clinical Research  
Infrastructure

## Biomedical Research Units (BRUs)



**NOCRI**

NIHR Office for  
Clinical Research  
Infrastructure

# NEW MODELS FOR EFFECTIVE PARTNERSHIP

## NIHR Healthcare Technology Co-operatives (HTCs)

- Aims of the NIHR HTCs:
  - Act as a catalyst for NHS “pull” for the development of new medical devices, healthcare technologies and technology-dependent interventions
  - Focus on clinical areas and/or themes of high morbidity, which have high potential for improving quality of life of NHS patients and improving the effectiveness of healthcare services that support them
  - Work collaboratively with patients and patients groups, charities, industry and academics


## NIHR Healthcare Technology Co-operatives (HTCs)

- NIHR HTCs play a key role in:
  - The integration of clinical and patient need into the definition of technology and product concepts
  - Bringing partners together in close collaboration to **develop, test and improve product concepts** leading to clinical evaluation and demonstration of care pathway benefits
  - Reaching across primary and secondary care and care services, professional bodies and national networks of clinical champions

**NOCRI**

NIHR Office for  
Clinical Research  
Infrastructure

## NIHR Healthcare Technology Co-operatives (HTCs)



## NIHR Diagnostics Evidence Co-operatives (DECs)

- Aims of the DECs
  - Act as a catalyst for the generation of high-quality evidence of clinical validity, clinical utility, cost effectiveness and care pathway benefits of commercially-supplied IVDs that is sought by a range of users, for example:
    - NHS clinicians and NHS commissioners
    - Accredited providers of NHS pathology services
    - **Companies involved in the CE marking and marketing of IVDs**
    - NICE Diagnostic Assessment Programme

## NIHR Diagnostics Evidence Co-operatives (DECs)

- Aims of the DECs
  - Enable collaboration between clinicians and other healthcare professionals, patients and the **IVD industry**, staff of at least one accredited provider of NHS pathology services, NHS commissioners, academic researchers including health economists, and patient groups.
  - Create new, world-class methodologies for IVD assessment, where required.



# NIHR Diagnostics Evidence Co-operatives (DECs)

## Leeds Teaching Hospitals NHS Trust

Liver diseases, Musculoskeletal diseases, Renal diseases.

## Newcastle upon Tyne NHS Foundation Trust

Cancer, Cardiovascular disease and stroke, Genetics, Infection, Liver disease, Musculoskeletal disease, Respiratory, Transplantation.

## Oxford Health NHS Foundation Trust


Primary care IVDs: Horizon scanning and rapid reviews to identify new and emerging IVDs, Identifying unmet needs for IVDs, Integrating primary care with laboratory services, Patient, carer and clinician factors in implementing IVDs, improving evidence for primary care IVDs.

## Imperial College Healthcare NHS Trust

Cancer, Cardiovascular diseases, Gut health, Infectious diseases, Metabolic medicine, Primary Care, Respiratory diseases.




# Clinical Research Network support along the study lifecycle



NOCRI

NIHR Office for  
Clinical Research  
Infrastructure

# NIHR CRN Study start-up route map



# How do I submit my study for support?

Clinical Research Network

NHS  
National Institute for  
Health Research

## Information

Please note that the system may be unavailable during scheduled maintenance periods. These are Mondays and Wednesdays, 16.00-16.30 (GMT), and Fridays 15.30-16.00 (GMT). If you are logged in when the maintenance starts, the system will log you out and any unsaved data will be lost. Please be sure to save your submissions regularly.

## Login

Email (User name)\*

Password\*

[Sign in](#)[Forgotten Password?](#)[Submit a new query](#)

\* Required fields

## ...or, register here

Name\*

Email (User name)\*

Email confirmation\*

Company\* ?

Telephone\*

Preferred method of contact\*

No Preference

☐ \* I agree to the [Terms and Conditions](#)[Register](#)

\* Required fields



## Case Studies

National Institute for Health Research

NOCRI

CONNECTING EXCELLENCE

NIHR Office for Clinical Research Infrastructure

### Blood test - a simple diagnosis for Alzheimer's?

The NIHR is collaborating with industry in biomarker research that has significant potential to form the basis of simple blood tests for the diagnosis and management of Alzheimer's

### Alzheimer's Plasma Biomarker Study

The National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre (BRC) for Mental Health, in collaboration with Proteome Sciences and Merck Millipore, has successfully concluded a 1,000 sample Alzheimer's disease biomarker validation study.

Preliminary data generated by the NIHR Maudsley BRC and Proteome Sciences suggest that proteins in blood may act as biomarkers that could help to identify dementia in the pre-clinical phase, or to predict the progression from mild cognitive impairment to dementia. Working together, the NIHR, Merck Millipore and Proteome Sciences have now tested biomarker panels of between 11 and 16 proteins in a very large replication study. These biomarkers have significant potential to form the basis of a series of simple blood tests for the diagnosis and management of Alzheimer's.

Analysis of the study data will determine whether individual markers and defined marker panels have diagnostic and prognostic utility. Given the complexity of the data, full analysis will introduce further biomarkers to the three panels over the coming months and the collaboration is hopeful that collectively these will benefit patients and families suffering from the devastating effects of Alzheimer's.

It is estimated that 60 per cent of people with Alzheimer's have not been properly diagnosed and therefore are not being given vital drugs and care. The capability to distinguish between the levels and progression of the disease will enable drug developers to substantially improve patient care and people with mild cognitive impairment are likely to benefit the most from such disease-modifying drugs.

### Industry Collaborations

Professor Simon Lovestone, Director of the NIHR Biomedical Research Centre for Mental Health commented: "This is the largest study of plasma biomarkers to date that we are aware of, and builds on our earlier findings to identify diagnostic and prognostic signals in plasma. As new treatments for Alzheimer's disease are being developed, there is an increasing need for accurate and accessible markers of disease severity and progression. If our results are positive, we will move quickly to support the development of clinical tests based on these biomarker panels."

Dr Linda Meeh, Director of Marketing for Immunoassays and Multiplexing, from EMD Millipore noted: "There is a need for assay tools that enable greater insight into the biochemical changes in key proteins in neurodegenerative disease research. The panels of biomarkers are part of the MILLIPLEX MAP portfolio, based on Luminex® xMAP® technology. These assays provide a high-throughput, multiplexed method that is more specific and sensitive than traditional single analyte methods, and provide the advantage of generating more data with less sample."

Christopher Pearce, CEO of Proteome Sciences, said: "This study is a major step towards a series of simple blood tests that would facilitate the early diagnosis and management of Alzheimer's. Such tests will address a major unmet need and will have widespread application and commercial value. Given the complexity of the data, we expect that the full analysis will introduce further biomarkers to the three panels we have already generated. We are hopeful that collectively these will benefit patients and families suffering from the devastating effects of Alzheimer's."

### NIHR Dementia Translational Research Collaboration

Dementia research is characterised by considerable methodological and disciplinary diversity. Addressing the main research questions requires drawing on a wide range of scientific areas and global specialist expertise.

To meet the challenge, the UK Government established the NIHR Dementia Translational Research Collaboration to pull discoveries from basic science into real benefits for patients. Managed by NOCRI, the Collaboration comprises four new NIHR Dementia Biomedical Research Units as well as six NIHR Biomedical Research Centres with dementia-related research themes. These Units and Centres are world leaders in translational research, based within top university-NIHR partnerships. The Collaboration is a new and important part of the NIHR clinical research infrastructure and offers a unique opportunity to maximise the significant NIHR investment in dementia translational research.

As with all areas of unmet patient need, industry plays a crucial role in the development of new interventions to tackle dementia. Better collaboration between academia, the NHS and industry, with greater mutual transparency is vital. The opportunity for such collaboration has never been greater given global biopharma is opening up its development programmes to collaboration to access innovative new approaches to research and development.

The Dementia and Neurodegenerative Diseases Research Network (DeNDiRN) is part of the NIHR which supports the development, set up and delivery of dementia clinical research in the NHS. DeNDiRN is the link in the chain that connects researchers with patients and their carers throughout the research process.

A health research collaboration between the NIHR and:

South London and Maudsley

NIHR Foundation Trust

For further information, contact NOCRI:

- NIHR Office for Clinical Research Infrastructure (NOCRI), A305 Richmond House, 79 Whitehall, London SW1A 2NS
- NOCRI Mirosoft: [www.nocrf@nhs.uk](mailto:www.nocrf@nhs.uk)
- NOCRI E-Mail: [nocrf@nhs.uk](mailto:nocrf@nhs.uk)
- Twitter: @NIHR\_NOCRI

## FUTURE PLAYERS

- MRC
  - Molecular Pathology ‘Nodes’
    - Regional centres
    - Discovery, Evaluation & Adoption!
  - Competition Open
- Innovate UK (TSB)
  - Precision Medicine Catapult
  - Still to be announced formally

**NOCRI**


NIHR Office for  
Clinical Research  
Infrastructure

# **DEC *IN-VITRO* DIAGNOSTIC (IVD) DEVELOPMENT PATHWAY**

NOCRI

NIHR Office for  
Clinical Research  
Infrastructure

# IVD Development Pathway - Stakeholders






NOCRI

NIHR Office for  
Clinical Research  
Infrastructure

# IVD Development Pathway - Funding



NOCRI

NIHR Office for  
Clinical Research  
Infrastructure

*To work with the Partnerships or any of the NIHR  
infrastructure contact the team at:*

[nocri@nihr.ac.uk](mailto:nocri@nihr.ac.uk)

**[www.nocri.nihr.ac.uk](http://www.nocri.nihr.ac.uk)**